CAS 503605-66-1
:Adecatumumab
Description:
Adecatumumab is a monoclonal antibody designed for therapeutic use, primarily targeting the human epidermal growth factor receptor 2 (HER2). It is classified as an IgG1 isotype and is engineered to bind specifically to the extracellular domain of HER2, which is overexpressed in certain types of cancers, particularly breast cancer. The mechanism of action involves inhibiting cell proliferation and inducing apoptosis in HER2-positive tumor cells. Adecatumumab has been investigated in clinical trials for its efficacy in treating various malignancies, including breast cancer, and is notable for its potential to enhance the immune response against tumor cells. Its pharmacokinetics, safety profile, and therapeutic efficacy are subjects of ongoing research. As a biopharmaceutical, it is produced using recombinant DNA technology, and its development reflects the growing trend of targeted therapies in oncology. The CAS number 503605-66-1 uniquely identifies this compound in chemical databases, facilitating its study and application in medical research and treatment protocols.
Formula:Unspecified
Synonyms:- MT 201
- Immunoglobulin G1, anti-(human epithelial cell adhesion molecule Ep-CAM) (human monoclonal MT201 γ1-chain), disulfide with human monoclonal MT201 κ-chain, dimer
- Immunoglobulin G1, anti-(human antigen 17-1A) (human monoclonal MT201 γ1-chain), disulfide with human monoclonal MT201 κ-chain, dimer
- Adecatumumab
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
Adecatumumab
CAS:<p>Adecatumumab (MT201) is a whole-person IgG1 monoclonal antibody to human EpCAM.</p>Purity:> 95%Color and Shape:LiquidMolecular weight:147.52 kDaAdecatumumab
CAS:<p>Recombinant human IgG1 monoclonal antibody targeting the epithelial cell adhestion molecule (EpCAM)</p>
